Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Treasury Shares (2019 - 2025)

BridgeBio Pharma's Treasury Shares history spans 6 years, with the latest figure at $323.3 million for Q4 2025.

  • For Q4 2025, Treasury Shares rose 17.55% year-over-year to $323.3 million; the TTM value through Dec 2025 reached $323.3 million, up 17.55%, while the annual FY2025 figure was $323.3 million, 17.55% up from the prior year.
  • Treasury Shares for Q4 2025 was $7.6 million at BridgeBio Pharma, roughly flat from $7.6 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $7.6 million in Q1 2025 and bottomed at -$3.8 million in Q4 2021.
  • The 5-year median for Treasury Shares is $6.2 million (2022), against an average of $4.9 million.
  • The largest annual shift saw Treasury Shares soared 266.67% in 2021 before it changed 0.0% in 2022.
  • A 5-year view of Treasury Shares shows it stood at $275.0 million in 2021, then changed by 0.0% to $275.0 million in 2022, then changed by 0.0% to $275.0 million in 2023, then changed by 0.0% to $275.0 million in 2024, then rose by 17.55% to $323.3 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Treasury Shares are $323.3 million (Q4 2025), $323.3 million (Q3 2025), and $323.3 million (Q2 2025).